Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Translation and validation of European organization for research and treatment of cancer quality of life Questionnaire -C30 into Moroccan version for cancer patients in Morocco</title><author><name sortKey="Nejjari, Chakib" sort="Nejjari, Chakib" uniqKey="Nejjari C" first="Chakib" last="Nejjari">Chakib Nejjari</name><affiliation><nlm:aff id="I1">Department of Epidemiology and Public health, Faculty of Medicine, University Sidi Mohammed Ben Abdellah, Fez, Morocco</nlm:aff></affiliation></author><author><name sortKey="El Fakir, Samira" sort="El Fakir, Samira" uniqKey="El Fakir S" first="Samira" last="El Fakir">Samira El Fakir</name><affiliation><nlm:aff id="I1">Department of Epidemiology and Public health, Faculty of Medicine, University Sidi Mohammed Ben Abdellah, Fez, Morocco</nlm:aff></affiliation></author><author><name sortKey="Bendahhou, Karima" sort="Bendahhou, Karima" uniqKey="Bendahhou K" first="Karima" last="Bendahhou">Karima Bendahhou</name><affiliation><nlm:aff id="I1">Department of Epidemiology and Public health, Faculty of Medicine, University Sidi Mohammed Ben Abdellah, Fez, Morocco</nlm:aff></affiliation></author><author><name sortKey="El Rhazi, Karima" sort="El Rhazi, Karima" uniqKey="El Rhazi K" first="Karima" last="El Rhazi">Karima El Rhazi</name><affiliation><nlm:aff id="I1">Department of Epidemiology and Public health, Faculty of Medicine, University Sidi Mohammed Ben Abdellah, Fez, Morocco</nlm:aff></affiliation></author><author><name sortKey="Abda, Naima" sort="Abda, Naima" uniqKey="Abda N" first="Naima" last="Abda">Naima Abda</name><affiliation><nlm:aff id="I1">Department of Epidemiology and Public health, Faculty of Medicine, University Sidi Mohammed Ben Abdellah, Fez, Morocco</nlm:aff></affiliation></author><author><name sortKey="Zidouh, Ahmed" sort="Zidouh, Ahmed" uniqKey="Zidouh A" first="Ahmed" last="Zidouh">Ahmed Zidouh</name><affiliation><nlm:aff id="I2">Fondation Lalla Salma Prevention and Treatment of Cancers, Rabat, Morocco</nlm:aff></affiliation></author><author><name sortKey="Benider, Abdelatif" sort="Benider, Abdelatif" uniqKey="Benider A" first="Abdelatif" last="Benider">Abdelatif Benider</name><affiliation><nlm:aff id="I3">Oncology Center Ibn Rochd, Casablanca, Morocco</nlm:aff></affiliation></author><author><name sortKey="Errihani, Hassan" sort="Errihani, Hassan" uniqKey="Errihani H" first="Hassan" last="Errihani">Hassan Errihani</name><affiliation><nlm:aff id="I4">National Institute of Oncology, Rabat, Morocco</nlm:aff></affiliation></author><author><name sortKey="Bekkali, Rachid" sort="Bekkali, Rachid" uniqKey="Bekkali R" first="Rachid" last="Bekkali">Rachid Bekkali</name><affiliation><nlm:aff id="I2">Fondation Lalla Salma Prevention and Treatment of Cancers, Rabat, Morocco</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24721384</idno><idno type="pmc">3984435</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984435</idno><idno type="RBID">PMC:3984435</idno><idno type="doi">10.1186/1756-0500-7-228</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">000147</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000147</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Translation and validation of European organization for research and treatment of cancer quality of life Questionnaire -C30 into Moroccan version for cancer patients in Morocco</title><author><name sortKey="Nejjari, Chakib" sort="Nejjari, Chakib" uniqKey="Nejjari C" first="Chakib" last="Nejjari">Chakib Nejjari</name><affiliation><nlm:aff id="I1">Department of Epidemiology and Public health, Faculty of Medicine, University Sidi Mohammed Ben Abdellah, Fez, Morocco</nlm:aff></affiliation></author><author><name sortKey="El Fakir, Samira" sort="El Fakir, Samira" uniqKey="El Fakir S" first="Samira" last="El Fakir">Samira El Fakir</name><affiliation><nlm:aff id="I1">Department of Epidemiology and Public health, Faculty of Medicine, University Sidi Mohammed Ben Abdellah, Fez, Morocco</nlm:aff></affiliation></author><author><name sortKey="Bendahhou, Karima" sort="Bendahhou, Karima" uniqKey="Bendahhou K" first="Karima" last="Bendahhou">Karima Bendahhou</name><affiliation><nlm:aff id="I1">Department of Epidemiology and Public health, Faculty of Medicine, University Sidi Mohammed Ben Abdellah, Fez, Morocco</nlm:aff></affiliation></author><author><name sortKey="El Rhazi, Karima" sort="El Rhazi, Karima" uniqKey="El Rhazi K" first="Karima" last="El Rhazi">Karima El Rhazi</name><affiliation><nlm:aff id="I1">Department of Epidemiology and Public health, Faculty of Medicine, University Sidi Mohammed Ben Abdellah, Fez, Morocco</nlm:aff></affiliation></author><author><name sortKey="Abda, Naima" sort="Abda, Naima" uniqKey="Abda N" first="Naima" last="Abda">Naima Abda</name><affiliation><nlm:aff id="I1">Department of Epidemiology and Public health, Faculty of Medicine, University Sidi Mohammed Ben Abdellah, Fez, Morocco</nlm:aff></affiliation></author><author><name sortKey="Zidouh, Ahmed" sort="Zidouh, Ahmed" uniqKey="Zidouh A" first="Ahmed" last="Zidouh">Ahmed Zidouh</name><affiliation><nlm:aff id="I2">Fondation Lalla Salma Prevention and Treatment of Cancers, Rabat, Morocco</nlm:aff></affiliation></author><author><name sortKey="Benider, Abdelatif" sort="Benider, Abdelatif" uniqKey="Benider A" first="Abdelatif" last="Benider">Abdelatif Benider</name><affiliation><nlm:aff id="I3">Oncology Center Ibn Rochd, Casablanca, Morocco</nlm:aff></affiliation></author><author><name sortKey="Errihani, Hassan" sort="Errihani, Hassan" uniqKey="Errihani H" first="Hassan" last="Errihani">Hassan Errihani</name><affiliation><nlm:aff id="I4">National Institute of Oncology, Rabat, Morocco</nlm:aff></affiliation></author><author><name sortKey="Bekkali, Rachid" sort="Bekkali, Rachid" uniqKey="Bekkali R" first="Rachid" last="Bekkali">Rachid Bekkali</name><affiliation><nlm:aff id="I2">Fondation Lalla Salma Prevention and Treatment of Cancers, Rabat, Morocco</nlm:aff></affiliation></author></analytic><series><title level="j">BMC Research Notes</title><idno type="eISSN">1756-0500</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p>Understanding the effects of cancer on the quality of life of affected patients is critical to clinical research as well as to optimal management and care. The aim of this study was to adapt the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) questionnaire into Moroccan Arabic and to determine its psychometric properties. After translation, back translation and pretesting of the pre-final version, the translated version was submitted to a committee of professionals composed by oncologists and epidemiologists. The psychometric properties were tested in patients with cancer. Internal consistency was tested using Cronbach’s alpha and the test-retest reliability using interclass correlation coefficients. Construct validity was assessed by examining item-convergent and divergent validity. It was also tested using Spearman’s correlation between QLQ-C30 scales and EQ-5D.</p></sec><sec><title>Results</title><p>The study was conducted in 125 patients. The Moroccan version was internally reliable, Cronbach’s α was 0.87 for the total scale and ranged from 0.34 to 0.97 for the subscales. The intraclass correlation coefficient of the test-retest reliability ranged from 0.64 for “social functioning” to 0.89 for “physical activities” subscales. The instrument demonstrated a good construct and concomitant validity.</p></sec><sec><title>Conclusions</title><p>We have developed a semantically equivalent translation with cultural adaptation of EORTC QLQ-C30 questionnaire. The assessment of its measurement properties showed that it is quite reliable and a valid measure of the effect of cancer on the quality of life in Moroccan patients.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Redd, Wh" uniqKey="Redd W">WH Redd</name></author><author><name sortKey="Montgomery, Gh" uniqKey="Montgomery G">GH Montgomery</name></author><author><name sortKey="Duhamel, Kn" uniqKey="Duhamel K">KN DuHamel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gelber, Rd" uniqKey="Gelber R">RD Gelber</name></author><author><name sortKey="Goldhirsch, A" uniqKey="Goldhirsch A">A Goldhirsch</name></author><author><name sortKey="Cavalli, F" uniqKey="Cavalli F">F Cavalli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Johnson, J" uniqKey="Johnson J">J Johnson</name></author><author><name sortKey="Temple, R" uniqKey="Temple R">R Temple</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aaronson, Nk" uniqKey="Aaronson N">NK Aaronson</name></author><author><name sortKey="Ahmedzai, S" uniqKey="Ahmedzai S">S Ahmedzai</name></author><author><name sortKey="Bergman, B" uniqKey="Bergman B">B Bergman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guillemin, F" uniqKey="Guillemin F">F Guillemin</name></author><author><name sortKey="Bombardier, C" uniqKey="Bombardier C">C Bombardier</name></author><author><name sortKey="Beaton, D" uniqKey="Beaton D">D Beaton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lohr, Kn" uniqKey="Lohr K">KN Lohr</name></author><author><name sortKey="Aaronson, Nk" uniqKey="Aaronson N">NK Aaronson</name></author><author><name sortKey="Alomso, J" uniqKey="Alomso J">J Alomso</name></author><author><name sortKey="Burnam, Ma" uniqKey="Burnam M">MA Burnam</name></author><author><name sortKey="Patrick, Dl" uniqKey="Patrick D">DL Patrick</name></author><author><name sortKey="Perrin, Eb" uniqKey="Perrin E">EB Perrin</name></author><author><name sortKey="Roberts, Js" uniqKey="Roberts J">JS Roberts</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Herdman, M" uniqKey="Herdman M">M Herdman</name></author><author><name sortKey="Fox Rushby, J" uniqKey="Fox Rushby J">J Fox-Rushby</name></author><author><name sortKey="Badia, X" uniqKey="Badia X">X Badia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Beaton, D" uniqKey="Beaton D">D Beaton</name></author><author><name sortKey="Bombardier, C" uniqKey="Bombardier C">C Bombardier</name></author><author><name sortKey="Guillemin, F" uniqKey="Guillemin F">F Guillemin</name></author><author><name sortKey="Ferraz, Mb" uniqKey="Ferraz M">MB Ferraz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Streiner, Dl" uniqKey="Streiner D">DL Streiner</name></author><author><name sortKey="Norman, Gr" uniqKey="Norman G">GR Norman</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Fayers, Pm" uniqKey="Fayers P">PM Fayers</name></author><author><name sortKey="Aaronson, Nk" uniqKey="Aaronson N">NK Aaronson</name></author><author><name sortKey="Bjordal, K" uniqKey="Bjordal K">K Bjordal</name></author><author><name sortKey="Groenvold, M" uniqKey="Groenvold M">M Groenvold</name></author><author><name sortKey="Curran, D" uniqKey="Curran D">D Curran</name></author><author><name sortKey="Bottomley, A" uniqKey="Bottomley A">A Bottomley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cronbach, Lj" uniqKey="Cronbach L">LJ Cronbach</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aaronson, Nk" uniqKey="Aaronson N">NK Aaronson</name></author><author><name sortKey="Bullinger, M" uniqKey="Bullinger M">M Bullinger</name></author><author><name sortKey="Ahmedzai, S" uniqKey="Ahmedzai S">S Ahmedzai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aaronson, Nk" uniqKey="Aaronson N">NK Aaronson</name></author><author><name sortKey="Ahmedzai, S" uniqKey="Ahmedzai S">S Ahmedzai</name></author><author><name sortKey="Bergman, B" uniqKey="Bergman B">B Bergman</name></author><author><name sortKey="Bullinger, M" uniqKey="Bullinger M">M Bullinger</name></author><author><name sortKey="Cull, A" uniqKey="Cull A">A Cull</name></author><author><name sortKey="Duez, Nj" uniqKey="Duez N">NJ Duez</name></author><author><name sortKey="Filiberti, A" uniqKey="Filiberti A">A Filiberti</name></author><author><name sortKey="Flechtner, H" uniqKey="Flechtner H">H Flechtner</name></author><author><name sortKey="Fleishman, Sb" uniqKey="Fleishman S">SB Fleishman</name></author><author><name sortKey="De Haes, Jcjm" uniqKey="De Haes J">JCJM de Haes</name></author><author><name sortKey="Kaasa, S" uniqKey="Kaasa S">S Kaasa</name></author><author><name sortKey="Klee, M" uniqKey="Klee M">M Klee</name></author><author><name sortKey="Osoba, D" uniqKey="Osoba D">D Osoba</name></author><author><name sortKey="Razavi, D" uniqKey="Razavi D">D Razavi</name></author><author><name sortKey="Rofe, Pb" uniqKey="Rofe P">PB Rofe</name></author><author><name sortKey="Schraub, S" uniqKey="Schraub S">S Schraub</name></author><author><name sortKey="Sneeuw, K" uniqKey="Sneeuw K">K Sneeuw</name></author><author><name sortKey="Sullivan, M" uniqKey="Sullivan M">M Sullivan</name></author><author><name sortKey="Takeda, F" uniqKey="Takeda F">F Takeda</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Montazeri, A" uniqKey="Montazeri A">A Montazeri</name></author><author><name sortKey="Harirchi, I" uniqKey="Harirchi I">I Harirchi</name></author><author><name sortKey="Vahdani, M" uniqKey="Vahdani M">M Vahdani</name></author><author><name sortKey="Khaleghi, F" uniqKey="Khaleghi F">F Khaleghi</name></author><author><name sortKey="Jarvandi, S" uniqKey="Jarvandi S">S Jarvandi</name></author><author><name sortKey="Ebrahimi, M" uniqKey="Ebrahimi M">M Ebrahimi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yun, Yh" uniqKey="Yun Y">YH Yun</name></author><author><name sortKey="Park, Ys" uniqKey="Park Y">YS Park</name></author><author><name sortKey="Lee, Es" uniqKey="Lee E">ES Lee</name></author><author><name sortKey="Bang, Sm" uniqKey="Bang S">SM Bang</name></author><author><name sortKey="Heo, Ds" uniqKey="Heo D">DS Heo</name></author><author><name sortKey="Park, Sy" uniqKey="Park S">SY Park</name></author><author><name sortKey="You, Ch" uniqKey="You C">CH You</name></author><author><name sortKey="West, K" uniqKey="West K">K West</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhao, H" uniqKey="Zhao H">H Zhao</name></author><author><name sortKey="Kanda, K" uniqKey="Kanda K">K Kanda</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoopman, R" uniqKey="Hoopman R">R Hoopman</name></author><author><name sortKey="Muller, Mj" uniqKey="Muller M">MJ Muller</name></author><author><name sortKey="Terwee, Cb" uniqKey="Terwee C">CB Terwee</name></author><author><name sortKey="Aaronson, Nk" uniqKey="Aaronson N">NK Aaronson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guyatt, Gh" uniqKey="Guyatt G">GH Guyatt</name></author><author><name sortKey="Feeny, Dh" uniqKey="Feeny D">DH Feeny</name></author><author><name sortKey="Patrick, Dl" uniqKey="Patrick D">DL Patrick</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article" xml:lang="en"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Res Notes</journal-id><journal-id journal-id-type="iso-abbrev">BMC Res Notes</journal-id><journal-title-group><journal-title>BMC Research Notes</journal-title></journal-title-group><issn pub-type="epub">1756-0500</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24721384</article-id><article-id pub-id-type="pmc">3984435</article-id><article-id pub-id-type="publisher-id">1756-0500-7-228</article-id><article-id pub-id-type="doi">10.1186/1756-0500-7-228</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Translation and validation of European organization for research and treatment of cancer quality of life Questionnaire -C30 into Moroccan version for cancer patients in Morocco</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Nejjari</surname><given-names>Chakib</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>cnejjari2000@yahoo.fr</email></contrib><contrib contrib-type="author" corresp="yes" id="A2"><name><surname>El Fakir</surname><given-names>Samira</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>elfakirsamira@yahoo.fr</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Bendahhou</surname><given-names>Karima</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>karimadahou@yahoo.fr</email></contrib><contrib contrib-type="author" id="A4"><name><surname>El Rhazi</surname><given-names>Karima</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>elrhazikarima@gmail.com</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Abda</surname><given-names>Naima</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>sondoss1@yahoo.fr</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Zidouh</surname><given-names>Ahmed</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>ahmed.zidouh@alsc.ma</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Benider</surname><given-names>Abdelatif</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>beniderabdel@yahoo.fr</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Errihani</surname><given-names>Hassan</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>h_errihani@yahoo.fr</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Bekkali</surname><given-names>Rachid</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>rachid.bekkali@alsc.ma</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Epidemiology and Public health, Faculty of Medicine, University Sidi Mohammed Ben Abdellah, Fez, Morocco</aff><aff id="I2"><label>2</label>Fondation Lalla Salma Prevention and Treatment of Cancers, Rabat, Morocco</aff><aff id="I3"><label>3</label>Oncology Center Ibn Rochd, Casablanca, Morocco</aff><aff id="I4"><label>4</label>National Institute of Oncology, Rabat, Morocco</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>10</day><month>4</month><year>2014</year></pub-date><volume>7</volume><fpage>228</fpage><lpage>228</lpage><history><date date-type="received"><day>23</day><month>4</month><year>2013</year></date><date date-type="accepted"><day>2</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>Copyright © 2014 Nejjari et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Nejjari et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1756-0500/7/228"></self-uri><abstract><sec><title>Background</title><p>Understanding the effects of cancer on the quality of life of affected patients is critical to clinical research as well as to optimal management and care. The aim of this study was to adapt the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) questionnaire into Moroccan Arabic and to determine its psychometric properties. After translation, back translation and pretesting of the pre-final version, the translated version was submitted to a committee of professionals composed by oncologists and epidemiologists. The psychometric properties were tested in patients with cancer. Internal consistency was tested using Cronbach’s alpha and the test-retest reliability using interclass correlation coefficients. Construct validity was assessed by examining item-convergent and divergent validity. It was also tested using Spearman’s correlation between QLQ-C30 scales and EQ-5D.</p></sec><sec><title>Results</title><p>The study was conducted in 125 patients. The Moroccan version was internally reliable, Cronbach’s α was 0.87 for the total scale and ranged from 0.34 to 0.97 for the subscales. The intraclass correlation coefficient of the test-retest reliability ranged from 0.64 for “social functioning” to 0.89 for “physical activities” subscales. The instrument demonstrated a good construct and concomitant validity.</p></sec><sec><title>Conclusions</title><p>We have developed a semantically equivalent translation with cultural adaptation of EORTC QLQ-C30 questionnaire. The assessment of its measurement properties showed that it is quite reliable and a valid measure of the effect of cancer on the quality of life in Moroccan patients.</p></sec></abstract><kwd-group><kwd>Cancer</kwd><kwd>Quality of life</kwd><kwd>Reliability</kwd><kwd>Validity</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Understanding the effects of cancer on the quality of life of affected patients is critical to clinical research as well as to optimal management and care. Measurement of quality of life is helpful in guiding management decisions. Furthermore, it is useful to monitor the effect of therapy on patients’ quality of life. The use of quality of life measures is usually welcomed by patients who wish to express their concerns.</p><p>Patients with cancer, enter therapy with the recognition that therapy aimed to cure is often accompanied by side effects that have a negative impact on their quality of life [<xref ref-type="bibr" rid="B1">1</xref>]. In recent years, many clinical cancer treatment research protocols have included a quality of life feature to evaluate the balance between side effects and quality of life during sometimes highly toxic treatment regimens [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>].</p><p>Quality of life addresses not only functional abilities, but also symptoms, side effects, and other issues such as social, psychological, spiritual, family, and financial aspects. The assessment of quality of life is becoming a standard component in the overall care of patients with cancer. Its main use in clinical trials has been to provide an additional outcome measure in the comparisons of different oncological treatment regimens.</p><p>In Morocco, there is no experience with patient-reported measurements of health-related quality of life in cancer patients. The availability of valid and reliable Moroccan version of quality of life instruments is critical to collect such measurement. Any tool designed to measure quality of life should be multidimensional, subjective, useful in setting, valid, and reliable.</p><p>One of the most popular instruments used with cancer patients is the EORTC QLQ-C30 [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Culturally adapting an existing instrument rather than composing a new one has several advantages. The cost and time-consuming process of developing a new test is avoided, and the use of standard measure permits cross-cultural comparisons [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Cross-cultural adaptation of a quality of life instrument is a step-wise process [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>].</p><p>This incremental methodological approach has become even more essential as increasing experiences have accumulated about cultural differences in the measurement of quality of life, and the recognition of different type of “equivalence” between cultures [<xref ref-type="bibr" rid="B7">7</xref>]. However, most adaptation process consists of two primary steps: assessment of the equivalence between the source instrument and the instrument being adapted, and evaluation of the measurement properties of the adapted instrument.</p><p>The aims of the current study were to translate into Moroccan Arabic and culturally adapt the EORTC QLQ-C30 (version 3.0), and to assess the psychometric properties of this translation.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Translation and cultural adaptation of the EORTC QLQ-C30</title><p>The EORTC QLQ-C30 is a 30-item questionnaire composed of nine multi-item scales and six single items. We followed the published guidelines for cross-cultural adaptation of health-related quality of life measurements [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. As only well-educated Moroccans have a good command of the official language in Morocco, Standard-Arabic, we translated the questionnaire into the oral language commonly spoken among Moroccan people: Moroccan Arabic. Some words could not be translated literally into Moroccan-Arabic, so they were replaced with a short description. For example, there are no Moroccan-Arabic equivalents for the words ‘Hobby’ or ‘quality’. In these cases a Standard-Arabic word was used in addition to the short description.</p></sec><sec><title>Patient recruitment</title><p>Between October and November 2009, cancer patients were recruited from the two main oncology centers in the country (National institute of oncology in Rabat and oncology center of Ibn Rochd hospital in Casablanca). Patients attending these two centers are from around the country (north, center and south). The sample size was defined according to Streiner curve [<xref ref-type="bibr" rid="B9">9</xref>] for an ICC of 0.70 and a precision of ± 0.10. Patients were eligible if they were at least 18 years old, had a confirmed diagnosis of cancer and spoke Moroccan Arabic. Ethical approval was obtained from the ethics committees in the University Hospital Center Hassan II in Fez- Morocco and all the subjects were informed of the conditions related to the study and gave their written, informed consent.</p></sec><sec><title>Instruments and procedures</title><p>The Arabic version of the EORTC QLQ-C30 were administered to patients by two different interviewers. The order of interviewers was randomly defined.</p><p>The same questionnaire was re- administered three to ten days later to assess reproducibility.</p><p>All participants were also asked to fill in the Euroquol 5 Dimension (EQ-5D) questionnaire which is a standardized instrument to measure health outcome. It provides a simple descriptive profile and a single index value of health status ranging from 0 (death) to 1 (perfect health). EQ-5D consists of five questions covering the dimensions of mobility, self-care, usual activities, pain/discomfort and anxiety/depression, each with three levels of response. The psychometric properties of the Moroccan version were adequate. The Kappa coefficient ranged from 0.49 to 0.92, the intraclass correlation coefficient (ICC) was 0.92 and good correlations between EQ-5D and SF-36 dimensions were noted (r = 0.53 to 0.85) [<xref ref-type="bibr" rid="B10">10</xref>].</p><p>Participants provided socio-demographic and clinical data and a measure of pain on a visual analogical scale(VAS).</p></sec><sec><title>Statistical analysis</title><p>Scores on the items and scales were linearly transformed to a scale from 0 to 100. A high score for a functional scale represents a healthy level of functioning, a high score for the global health status represents a high quality of life, but a high score for a symptom scale/item represents a high level of symptomatology [<xref ref-type="bibr" rid="B11">11</xref>].</p><p>Descriptive statistics were generated to evaluate missing data and score distributions (i.e. mean, range, floor and ceiling effects).</p><p>Internal consistency reliability of the multi-item scales was assessed by Cronbach’s coefficient α. A value of 0.70 or greater was considered as adequate [<xref ref-type="bibr" rid="B12">12</xref>]. Inter-rater and test-retest reliabilities were assessed by the intraclass correlation coefficient (ICC), derived from a two-way analysis of variance in a random effect model.</p><p>Multitrait scaling analysis were employed to examine item-convergent validity (item-scale correlations should be >0.40) and item-discriminant validity (items should correlate significantly higher with their own scale than with other scales). Construct validity was also tested using Spearman’s correlation between QLQ-C30 scales and EQ-5D.</p><p>All statistical analyses were performed using SPSS 17.0.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Sample socio-demographic and clinical characteristics</title><p>125 patients participated in the study, 65 were recruited in Rabat and 60 in Casablanca. Sociodemographic and clinical characteristics of the study sample are shown in Table <xref ref-type="table" rid="T1">1</xref>. Participants ranged in age from 19 to 81 years; the mean age was 44 years (<italic>SD</italic>: 16). 54% were males and 57% were illiterate. The most common primary cancer diagnoses were cancer of lung (17%), breast (16%) and cavum (9%). 67 patients underwent the third assessment.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Patients’ sociodemographic and clinical characteristics</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col></colgroup><thead valign="top"><tr><th align="left"> </th><th align="center"><bold>N (%)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold>Center</bold><hr></hr></td><td align="center" valign="bottom"> <hr></hr></td></tr><tr><td align="left" valign="bottom"> Rabat<hr></hr></td><td align="center" valign="bottom">65 (52.0)<hr></hr></td></tr><tr><td align="left" valign="bottom"> Casablanca<hr></hr></td><td align="center" valign="bottom">60 (48.0)<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Gender</bold><hr></hr></td><td align="center" valign="bottom"> <hr></hr></td></tr><tr><td align="left" valign="bottom"> Female<hr></hr></td><td align="center" valign="bottom">57 (45.6)<hr></hr></td></tr><tr><td align="left" valign="bottom"> Male<hr></hr></td><td align="center" valign="bottom">68 (54.4)<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Marital status</bold><hr></hr></td><td align="center" valign="bottom"> <hr></hr></td></tr><tr><td align="left" valign="bottom"> Single<hr></hr></td><td align="center" valign="bottom">26 (20.8)<hr></hr></td></tr><tr><td align="left" valign="bottom"> Married<hr></hr></td><td align="center" valign="bottom">80 (64.0)<hr></hr></td></tr><tr><td align="left" valign="bottom"> Widowed<hr></hr></td><td align="center" valign="bottom">6 (4.8)<hr></hr></td></tr><tr><td align="left" valign="bottom"> Divorced<hr></hr></td><td align="center" valign="bottom">5 (4.0)<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Employment status</bold><hr></hr></td><td align="center" valign="bottom"> <hr></hr></td></tr><tr><td align="left" valign="bottom"> Employed<hr></hr></td><td align="center" valign="bottom">33 (27,5)<hr></hr></td></tr><tr><td align="left" valign="bottom"> Unemployed<hr></hr></td><td align="center" valign="bottom">29 (24.2)<hr></hr></td></tr><tr><td align="left" valign="bottom"> Student<hr></hr></td><td align="center" valign="bottom">4 (3.3)<hr></hr></td></tr><tr><td align="left" valign="bottom"> House wife<hr></hr></td><td align="center" valign="bottom">49 (40.8)<hr></hr></td></tr><tr><td align="left" valign="bottom"> Retired<hr></hr></td><td align="center" valign="bottom">5 (41.7)<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Education</bold><hr></hr></td><td align="center" valign="bottom"> <hr></hr></td></tr><tr><td align="left" valign="bottom"> Illiterate<hr></hr></td><td align="center" valign="bottom">71 (57.3)<hr></hr></td></tr><tr><td align="left" valign="bottom"> Primary<hr></hr></td><td align="center" valign="bottom">19 (15.3)<hr></hr></td></tr><tr><td align="left" valign="bottom"> Secondary<hr></hr></td><td align="center" valign="bottom">30 (24.2)<hr></hr></td></tr><tr><td align="left" valign="bottom"> University<hr></hr></td><td align="center" valign="bottom">4 (3.2)<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Residence</bold><hr></hr></td><td align="center" valign="bottom"> <hr></hr></td></tr><tr><td align="left" valign="bottom"> Urban<hr></hr></td><td align="center" valign="bottom">80 (64.5)<hr></hr></td></tr><tr><td align="left" valign="bottom"> Rural<hr></hr></td><td align="center" valign="bottom">44 (35.5)<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Primary cancer diagnosis</bold><hr></hr></td><td align="center" valign="bottom"> <hr></hr></td></tr><tr><td align="left" valign="bottom"> Lung<hr></hr></td><td align="center" valign="bottom">21 (16.8)<hr></hr></td></tr><tr><td align="left" valign="bottom"> Breast<hr></hr></td><td align="center" valign="bottom">20 (16.0)<hr></hr></td></tr><tr><td align="left" valign="bottom"> Cavum<hr></hr></td><td align="center" valign="bottom">11 (8.8)<hr></hr></td></tr><tr><td align="left" valign="bottom"> Cervical cancer<hr></hr></td><td align="center" valign="bottom">10 (8.0)<hr></hr></td></tr><tr><td align="left" valign="bottom"> Colorectal<hr></hr></td><td align="center" valign="bottom">10 (8.0)<hr></hr></td></tr><tr><td align="left" valign="bottom"> Stomach<hr></hr></td><td align="center" valign="bottom">4 (3.2)<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>Age</bold> mean (SD)<hr></hr></td><td align="center" valign="bottom">44.2 (16.0)<hr></hr></td></tr><tr><td align="left" valign="bottom"><bold>EQ-5D</bold> mean (SD)<hr></hr></td><td align="center" valign="bottom">0.49 (0.35)<hr></hr></td></tr><tr><td align="left"><bold>Third assessment (test-retest)</bold></td><td align="center">85 (68.0)</td></tr></tbody></table></table-wrap></sec><sec><title>Acceptability</title><p>The average time to complete the QLQ-C30 was 10 min. On average, missing data rate for items was 1.1% (range 0–1.6%). The items that had missing responses were item 4 of “Physical functioning” scale, items 6 and 7 of “Role functioning”, item 8 “dyspnoea”, items 18 and 19 of “fatigue” and “pain” and item 30 of “global health status”.</p></sec><sec><title>Descriptive statistics</title><p>Scores distributions are shown in Table <xref ref-type="table" rid="T2">2</xref>. The scores for different scales ranged from 43.4 to 88.7. “Role functioning” scale had the lower score (median 33.3), “social functioning” scale had a median score at 100. Financial difficulties were common with a median at 100. The most frequent symptoms were nausea and vomiting, appetite loss and pain.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Subscale scores and floor and ceiling effect</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col></colgroup><thead valign="top"><tr><th align="left"> </th><th align="left"><bold>N</bold></th><th align="left"><bold>Median</bold></th><th align="left"><bold>Mean</bold></th><th align="left"><bold>Standard deviation</bold></th><th align="left"><bold>Floor effect</bold><sup><bold>a </bold></sup><bold>(%)</bold></th><th align="left"><bold>Ceiling effect</bold><sup><bold>b </bold></sup><bold>(%)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Physical functioning<hr></hr></td><td align="left" valign="bottom">125<hr></hr></td><td align="left" valign="bottom">60.00<hr></hr></td><td align="left" valign="bottom">53.86<hr></hr></td><td align="left" valign="bottom">31.76<hr></hr></td><td align="left" valign="bottom">7.9<hr></hr></td><td align="left" valign="bottom">10.3<hr></hr></td></tr><tr><td align="left" valign="bottom">Role functioning<hr></hr></td><td align="left" valign="bottom">125<hr></hr></td><td align="left" valign="bottom">33.33<hr></hr></td><td align="left" valign="bottom">43.41<hr></hr></td><td align="left" valign="bottom">43.9<hr></hr></td><td align="left" valign="bottom">42.1<hr></hr></td><td align="left" valign="bottom">30.2<hr></hr></td></tr><tr><td align="left" valign="bottom">Emotional functioning<hr></hr></td><td align="left" valign="bottom">124<hr></hr></td><td align="left" valign="bottom">66.67<hr></hr></td><td align="left" valign="bottom">64.07<hr></hr></td><td align="left" valign="bottom">33.00<hr></hr></td><td align="left" valign="bottom">9.5<hr></hr></td><td align="left" valign="bottom">27.0<hr></hr></td></tr><tr><td align="left" valign="bottom">cognitive functioning<hr></hr></td><td align="left" valign="bottom">125<hr></hr></td><td align="left" valign="bottom">66.67<hr></hr></td><td align="left" valign="bottom">68.80<hr></hr></td><td align="left" valign="bottom">31.11<hr></hr></td><td align="left" valign="bottom">4.8<hr></hr></td><td align="left" valign="bottom">38.1<hr></hr></td></tr><tr><td align="left" valign="bottom">Social functioning<hr></hr></td><td align="left" valign="bottom">125<hr></hr></td><td align="left" valign="bottom">100<hr></hr></td><td align="left" valign="bottom">88.67<hr></hr></td><td align="left" valign="bottom">24.10<hr></hr></td><td align="left" valign="bottom">3.2<hr></hr></td><td align="left" valign="bottom">73.8<hr></hr></td></tr><tr><td align="left" valign="bottom">Global health status<hr></hr></td><td align="left" valign="bottom">125<hr></hr></td><td align="left" valign="bottom">50.00<hr></hr></td><td align="left" valign="bottom">53.25<hr></hr></td><td align="left" valign="bottom">30.31<hr></hr></td><td align="left" valign="bottom">7.1<hr></hr></td><td align="left" valign="bottom">11.9<hr></hr></td></tr><tr><td align="left" valign="bottom">Fatigue<hr></hr></td><td align="left" valign="bottom">125<hr></hr></td><td align="left" valign="bottom">44.44<hr></hr></td><td align="left" valign="bottom">45.56<hr></hr></td><td align="left" valign="bottom">33.15<hr></hr></td><td align="left" valign="bottom">19.0<hr></hr></td><td align="left" valign="bottom">11.1<hr></hr></td></tr><tr><td align="left" valign="bottom">Nausea and vomiting<hr></hr></td><td align="left" valign="bottom">125<hr></hr></td><td align="left" valign="bottom">66.67<hr></hr></td><td align="left" valign="bottom">64.13<hr></hr></td><td align="left" valign="bottom">35.67<hr></hr></td><td align="left" valign="bottom">11.1<hr></hr></td><td align="left" valign="bottom">36.5<hr></hr></td></tr><tr><td align="left" valign="bottom">Pain<hr></hr></td><td align="left" valign="bottom">125<hr></hr></td><td align="left" valign="bottom">66.67<hr></hr></td><td align="left" valign="bottom">60.27<hr></hr></td><td align="left" valign="bottom">38.03<hr></hr></td><td align="left" valign="bottom">16.7<hr></hr></td><td align="left" valign="bottom">33.3<hr></hr></td></tr><tr><td align="left" valign="bottom">Dyspnoea<hr></hr></td><td align="left" valign="bottom">124<hr></hr></td><td align="left" valign="bottom">0.00<hr></hr></td><td align="left" valign="bottom">27.15<hr></hr></td><td align="left" valign="bottom">35.65<hr></hr></td><td align="left" valign="bottom">57.1<hr></hr></td><td align="left" valign="bottom">9.5<hr></hr></td></tr><tr><td align="left" valign="bottom">Insomnia<hr></hr></td><td align="left" valign="bottom">125<hr></hr></td><td align="left" valign="bottom">0.00<hr></hr></td><td align="left" valign="bottom">33.86<hr></hr></td><td align="left" valign="bottom">42.33<hr></hr></td><td align="left" valign="bottom">57.9<hr></hr></td><td align="left" valign="bottom">20.6<hr></hr></td></tr><tr><td align="left" valign="bottom">Appetite loss<hr></hr></td><td align="left" valign="bottom">125<hr></hr></td><td align="left" valign="bottom">66.67<hr></hr></td><td align="left" valign="bottom">61.33<hr></hr></td><td align="left" valign="bottom">41.35<hr></hr></td><td align="left" valign="bottom">24.6<hr></hr></td><td align="left" valign="bottom">44.4<hr></hr></td></tr><tr><td align="left" valign="bottom">Constipation<hr></hr></td><td align="left" valign="bottom">125<hr></hr></td><td align="left" valign="bottom">0.00<hr></hr></td><td align="left" valign="bottom">26.93<hr></hr></td><td align="left" valign="bottom">38.73<hr></hr></td><td align="left" valign="bottom">62.7<hr></hr></td><td align="left" valign="bottom">15.1<hr></hr></td></tr><tr><td align="left" valign="bottom">Diarrhoea<hr></hr></td><td align="left" valign="bottom">125<hr></hr></td><td align="left" valign="bottom">0.00<hr></hr></td><td align="left" valign="bottom">18.40<hr></hr></td><td align="left" valign="bottom">30.95<hr></hr></td><td align="left" valign="bottom">68.3<hr></hr></td><td align="left" valign="bottom">6.3<hr></hr></td></tr><tr><td align="left">Financial difficulties</td><td align="left">125</td><td align="left">100</td><td align="left">77.33</td><td align="left">36.32</td><td align="left">13.5</td><td align="left">65.9</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>percentage of the lowest modality.</p><p><sup>b</sup>percentage of the highest modality.</p></table-wrap-foot></table-wrap><p>High ceiling or floor effects were observed for the “Role functioning”, “cognitive functioning” and “social functioning” scales and for most of the single item symptom scales (Table <xref ref-type="table" rid="T2">2</xref>).</p></sec><sec><title>Reliability</title><p>Cronbach’s α was 0.87 for the total scale and ranged from 0.34 for “cognitive functioning” to 0.94 for “role functioning”, indicating good internal consistency (Table <xref ref-type="table" rid="T3">3</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Internal consistency and reliability of the EORTC QLQ-C30</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="top"><tr><th rowspan="2" align="left"> </th><th rowspan="2" align="center"><bold>Cronbach’s α</bold></th><th colspan="2" align="center" valign="bottom"><bold>Reliability ICC (IC 95%)</bold><hr></hr></th></tr><tr><th align="center"><bold>Inter-ratter</bold></th><th align="center"><bold>Test-retest</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Physical functioning<hr></hr></td><td align="center" valign="bottom">0.84<hr></hr></td><td align="center" valign="bottom">0.92 [0.88-0.94]<hr></hr></td><td align="center" valign="bottom">0.89 [0.85-0.93]<hr></hr></td></tr><tr><td align="left" valign="bottom">Role functioning<hr></hr></td><td align="center" valign="bottom">0.94<hr></hr></td><td align="center" valign="bottom">0.82 [0.75-0.87]<hr></hr></td><td align="center" valign="bottom">0.80 [0.71-0.87]<hr></hr></td></tr><tr><td align="left" valign="bottom">Emotional functioning<hr></hr></td><td align="center" valign="bottom">0.89<hr></hr></td><td align="center" valign="bottom">0.82 [0.76-0.87]<hr></hr></td><td align="center" valign="bottom">0.82 [0.74-0.88]<hr></hr></td></tr><tr><td align="left" valign="bottom">cognitive functioning<hr></hr></td><td align="center" valign="bottom">0.34<hr></hr></td><td align="center" valign="bottom">0.83 [0.77-0.88]<hr></hr></td><td align="center" valign="bottom">0.72 [0.61-0.81]<hr></hr></td></tr><tr><td align="left" valign="bottom">Social functioning<hr></hr></td><td align="center" valign="bottom">0.80<hr></hr></td><td align="center" valign="bottom">0.78 [0.69-0.84]<hr></hr></td><td align="center" valign="bottom">0.64 [0.50-0.75]<hr></hr></td></tr><tr><td align="left" valign="bottom">Global health status<hr></hr></td><td align="center" valign="bottom">0.87<hr></hr></td><td align="center" valign="bottom">0.84 [0.78-0.89]<hr></hr></td><td align="center" valign="bottom">0.76 [0.66-0.84]<hr></hr></td></tr><tr><td align="left" valign="bottom">Fatigue<hr></hr></td><td align="center" valign="bottom">0.83<hr></hr></td><td align="center" valign="bottom">0.82 [0.75-0.87]<hr></hr></td><td align="center" valign="bottom">0.84 [0.76-0.89]<hr></hr></td></tr><tr><td align="left" valign="bottom">Nausea and vomiting<hr></hr></td><td align="center" valign="bottom">0.74<hr></hr></td><td align="center" valign="bottom">0.83 [0.77-0.88]<hr></hr></td><td align="center" valign="bottom">0.78 [0.67-0.85]<hr></hr></td></tr><tr><td align="left" valign="bottom">Pain<hr></hr></td><td align="center" valign="bottom">0.78<hr></hr></td><td align="center" valign="bottom">0.90 [0.86-0.93]<hr></hr></td><td align="center" valign="bottom">0.82 [0.74-0.88]<hr></hr></td></tr><tr><td align="left" valign="bottom">Dyspnoea<hr></hr></td><td align="center" valign="bottom">-<hr></hr></td><td align="center" valign="bottom">0.78 [0.68-0.84]<hr></hr></td><td align="center" valign="bottom">0.78 [0.68-0.85]<hr></hr></td></tr><tr><td align="left" valign="bottom">Insomnia<hr></hr></td><td align="center" valign="bottom">-<hr></hr></td><td align="center" valign="bottom">0.73 [0.63-0.81]<hr></hr></td><td align="center" valign="bottom">0.74 [0.62-0.82]<hr></hr></td></tr><tr><td align="left" valign="bottom">Appetite loss<hr></hr></td><td align="center" valign="bottom">-<hr></hr></td><td align="center" valign="bottom">0.83 [0.77-0.88]<hr></hr></td><td align="center" valign="bottom">0.75 [0.65-0.83]<hr></hr></td></tr><tr><td align="left" valign="bottom">Constipation<hr></hr></td><td align="center" valign="bottom">-<hr></hr></td><td align="center" valign="bottom">0.89 [0.85-0.92]<hr></hr></td><td align="center" valign="bottom">0.82 [0.73-0.88]<hr></hr></td></tr><tr><td align="left" valign="bottom">Diarrhoea<hr></hr></td><td align="center" valign="bottom">-<hr></hr></td><td align="center" valign="bottom">0.78 [0.70-0.84]<hr></hr></td><td align="center" valign="bottom">0.75 [0.64-0.83]<hr></hr></td></tr><tr><td align="left">Financial difficulties</td><td align="center">-</td><td align="center">0.74 [0.65-0.81]</td><td align="center">0.80 [0.71-0.87]</td></tr></tbody></table></table-wrap><p>Inter-ratter reliability was substantial for the nine scales and the independent items (Table <xref ref-type="table" rid="T3">3</xref>).</p><p>Test-retest reliability was assessed using the intraclass correlation coefficient, which ranged from 0.64 for “social functioning” to 0.89 for “physical activities”.</p></sec><sec><title>Construct validity</title><p>All items exceeded the 0.4 criterion for convergent validity in all scales (Table <xref ref-type="table" rid="T4">4</xref>).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Multitrait scaling analysis of the EORTC QLQ-C30 questionnaire (Moroccan Arabic Version)</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="top"><tr><th align="left"><bold>Scales</bold></th><th align="center"><bold>Item convergent validity (item-own scale correlation)</bold></th><th align="center"><bold>Item convergent validity scaling succes</bold><sup><bold>a</bold></sup></th><th align="center"><bold>Item discriminant validity scaling succes</bold><sup><bold>b</bold></sup></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Physical functioning<hr></hr></td><td align="center" valign="bottom">0.72-0.86<hr></hr></td><td align="center" valign="bottom">5/5<hr></hr></td><td align="center" valign="bottom">40/40<hr></hr></td></tr><tr><td align="left" valign="bottom">Role functioning<hr></hr></td><td align="center" valign="bottom">0.98-0.98<hr></hr></td><td align="center" valign="bottom">2/2<hr></hr></td><td align="center" valign="bottom">16/16<hr></hr></td></tr><tr><td align="left" valign="bottom">Emotional functioning<hr></hr></td><td align="center" valign="bottom">0.85-0.89<hr></hr></td><td align="center" valign="bottom">4/4<hr></hr></td><td align="center" valign="bottom">32/32<hr></hr></td></tr><tr><td align="left" valign="bottom">cognitive functioning<hr></hr></td><td align="center" valign="bottom">0.73-0.82<hr></hr></td><td align="center" valign="bottom">2/2<hr></hr></td><td align="center" valign="bottom">16/16<hr></hr></td></tr><tr><td align="left" valign="bottom">Social functioning<hr></hr></td><td align="center" valign="bottom">0.89-0.92<hr></hr></td><td align="center" valign="bottom">2/2<hr></hr></td><td align="center" valign="bottom">16/16<hr></hr></td></tr><tr><td align="left" valign="bottom">Global health status<hr></hr></td><td align="center" valign="bottom">0.94-0.94<hr></hr></td><td align="center" valign="bottom">2/2<hr></hr></td><td align="center" valign="bottom">16/16<hr></hr></td></tr><tr><td align="left" valign="bottom">Fatigue<hr></hr></td><td align="center" valign="bottom">0.81-0.89<hr></hr></td><td align="center" valign="bottom">3/3<hr></hr></td><td align="center" valign="bottom">20/24<hr></hr></td></tr><tr><td align="left" valign="bottom">Nausea and vomiting<hr></hr></td><td align="center" valign="bottom">0.89-0.90<hr></hr></td><td align="center" valign="bottom">2/2<hr></hr></td><td align="center" valign="bottom">16/16<hr></hr></td></tr><tr><td align="left">Pain</td><td align="center">0.90-0.93</td><td align="center">2/2</td><td align="center">16/16</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Number of item-scale correlations greater than 0.40/total number of item-scale correlations.</p><p><sup>b</sup>number of correlations of items with own scales significantly higher than correlations with other scale/total number of correlations.</p></table-wrap-foot></table-wrap><p>Item-discriminant validity was 100% successful for all items except item 10, 12 and 18. “Fatigue” items were highly correlated with “Physical functioning” scale and item 10 was highly correlated with “global health status”.</p><p>The EQ-5D was highly correlated with “Physical functioning” and “Emotional functioning”, and moderately correlated with “Role functioning”, “Global health status” and “Fatigue”. VAS pain was moderately correlated with “pain” scale (Table <xref ref-type="table" rid="T5">5</xref>).</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Correlations between EORTC QLQ-C30 scales, EQ-5D and VAS pain</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead><tr><th align="left" valign="top"> <hr></hr></th><th colspan="9" align="center" valign="bottom"><bold>EORTC QLQ-C30</bold><hr></hr></th></tr><tr><th align="left"> </th><th align="center"><bold>PF</bold></th><th align="center"><bold>RF</bold></th><th align="center"><bold>EF</bold></th><th align="center"><bold>CF</bold></th><th align="center"><bold>SF</bold></th><th align="center"><bold>GHS</bold></th><th align="center"><bold>FA</bold></th><th align="center"><bold>NV</bold></th><th align="center"><bold>PA</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">EQ-5D<hr></hr></td><td align="center" valign="bottom">0.66<hr></hr></td><td align="center" valign="bottom">0.50<hr></hr></td><td align="center" valign="bottom">0.43<hr></hr></td><td align="center" valign="bottom">0.44<hr></hr></td><td align="center" valign="bottom">0.22<hr></hr></td><td align="center" valign="bottom">-0.41<hr></hr></td><td align="center" valign="bottom">0.55<hr></hr></td><td align="center" valign="bottom">0.27<hr></hr></td><td align="center" valign="bottom">0.62<hr></hr></td></tr><tr><td align="left">VAS pain</td><td align="center">-0.25</td><td align="center">-0.32</td><td align="center">-0.25</td><td align="center">-0.32</td><td align="center">-0.06</td><td align="center">0.27</td><td align="center">-0.28</td><td align="center">-0.16</td><td align="center">-0.59</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In this paper, we report the result of a cross-cultural adaptation and evaluation of the psychometric properties of the Moroccan Arabic version of the EORTC QLQ-C30.</p><p>This instrument has been developed in 1987 by the European Organisation for Research and Treatment of Cancer. The EORTC QLQ-C30 has been internationally validated [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B17">17</xref>], and is currently available in more than 81 languages (<ext-link ext-link-type="uri" xlink:href="http://www.eortc.be">http://www.eortc.be</ext-link>). It was validated to use among Moroccan ethnic minority cancer patients in the Netherlands [<xref ref-type="bibr" rid="B18">18</xref>]. However the majority of Moroccan immigrants living in Netherlands were from rural areas of north Morocco where the most common oral language is “Tarifit” and where the educational and literacy levels are lower than national standards. To our knowledge, it is the first Moroccan Arabic validation of a cancer quality of life instrument. This new validated scale will provide information on the functional health and well-being of Moroccan patients in order to provide them with optimal health care services.</p><p>To obtain this scale, we followed the international guidelines for cross-cultural adaptation of health-related quality of life measures [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B8">8</xref>].</p><p>The average time required to complete the questionnaire was similar to that reported in earlier studies [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>].</p><p>Time between test and retest was three days on average. Streiner and Norman indicate that expert opinions regarding the appropriate interval vary from one hour to one year, depending on the task, but generally, a retest interval of 2 to 14 days is usually used [<xref ref-type="bibr" rid="B19">19</xref>].</p><p>The reliability and validity of the Moroccan Arabic version of the EORTC QLQ-C30 were satisfactory. The hypothesized scale structure of the questionnaire was largely confirmed. Cronbach’s alpha coefficient was high for all scales except “cognitive functioning”, indicating adequate internal reliability. Problems with the psychometric properties of “cognitive functioning” scale have been reported in other studies [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. Inter-ratter and test-retest reliability were confirmed by the ICC for the subscales, ICC inter-ratter ranged from 0.73 to 0.92 and test-retest from 0.64 to 0.89.</p><p>Construct validity was assessed by testing convergent and discriminant validity of the items, and the associations between the scores of each domain and the EQ-5D score. The most common concurrent scale used in validation studies was the SF36. We could not use this scale because it included 36 items, it could be hard for patients to complete the EORTC QLQ-C30 questionnaire twice and the SF36. The EQ-5D which is a short scale was preferred, especially since administration of the questionnaire need more time than auto-administration.</p><p>All items exceeded the 0.4 criterion for convergent validity on all scales. Item-discriminant validity was 100% successful for all items except three. “Fatigue” items were highly correlated with “physical functioning” scale, this result was also observed in the validation study among the Moroccan group living in Netherlands [<xref ref-type="bibr" rid="B18">18</xref>].</p><p>VAS pain was not highly correlated with “pain” scale because the EORTC QLQ-C30 pain scale measures pain during the past week and VAS pain gives an instantaneous measure during the interview.</p><p>Known group’s validity was not tested because the number of missing data about disease stage and treatment status was high.</p><p>Because of the high level of illiteracy, an interviewer had administered the questionnaire for all patients. Unlike northern countries, the questionnaire could not be used as an auto-administered questionnaire except for a minority of Moroccan population.</p><p>One of the limitations of this study is that responsiveness over time is not performed. We would recommend that additional studies be carried out with patients under active treatment in order to document the responsiveness.</p><p>Despite the fact that Arabic language is commonly spoken across the country, there are some other regional languages such as “Tarifit”, “Tamazight” and “Tachelhit”. But, the majority of these people speak also Arabic. Further validation should be specifically performed in these regions because inclusion of these patient groups in local or national clinical studies is essential.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>We conclude that the Moroccan Arabic version of the EORTC QLQ-C30 is a reliable and valid measure of the quality of life in cancer patients and can be used in cohort studies. However, confirmation of its responsiveness requires a formal study assessing the effect of a specific therapeutic intervention.</p></sec><sec><title>Abbreviations</title><p>EORTC QLQ-C30: the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-C30; EQ-5D: Euroquol 5 Dimension; ICC: Intraclass correlation coefficient; SF-36: 36-Item Short Form Health Survey; VAS: Visual analogical scale; SD: Standard deviation.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors’ contributions</title><p>CN has contributed to conception and design, acquisition of data, analysis and interpretation of data, have been involved in revising the manuscript critically and have given final approval of the version to be published; SE has contributed to conception and design, interpretation of data and have been involved in drafting the manuscript; KB has made substantial contribution to conception and design of data and has been involved in drafting the manuscript; KE has been involved in drafting the manuscript and have given final approval of the version to be published. NA has contributed to conception and design of data; AZ has contributed to conception and design of data. AB has made substantial contributions to conception and design of data; HE has made substantial contributions to conception and design of data; RB has reviewed the manuscript and has given final approval of the version to be published. All authors read and approved the manuscript.</p></sec></body><back><sec><title>Acknowledgment</title><p>We thank “<italic>Fondation Lalla Salma Prevention and Treatment of Cancers</italic>” and “<italic>Roche Laboratories</italic>” for their support.</p><p>We thank <italic>Dr Maryam Fourtassi</italic> for rereading this manuscript.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Redd</surname><given-names>WH</given-names></name><name><surname>Montgomery</surname><given-names>GH</given-names></name><name><surname>DuHamel</surname><given-names>KN</given-names></name><article-title>Behavioral intervention for cancer treatment side effects</article-title><source>J Natl Cancer Inst</source><year>2001</year><volume>93</volume><issue>11</issue><fpage>810</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1093/jnci/93.11.810</pub-id><pub-id pub-id-type="pmid">11390531</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Gelber</surname><given-names>RD</given-names></name><name><surname>Goldhirsch</surname><given-names>A</given-names></name><name><surname>Cavalli</surname><given-names>F</given-names></name><article-title>Quality of life adjusted evaluation of adjuvant therapies for operable breast cancer</article-title><source>Ann Intern Med</source><year>1991</year><volume>114</volume><issue>8</issue><fpage>621</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-114-8-621</pub-id><pub-id pub-id-type="pmid">2003707</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Temple</surname><given-names>R</given-names></name><article-title>Food and drug administration requirements for approval of new anticancer drugs</article-title><source>Cancer Treat Rep</source><year>1985</year><volume>69</volume><fpage>1155</fpage><lpage>1159</lpage><pub-id pub-id-type="pmid">4042094</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Ahmedzai</surname><given-names>S</given-names></name><name><surname>Bergman</surname><given-names>B</given-names></name><article-title>The European Organisation for Research and treatment of Cancer QLQ-C30: a quaity of life instrument for use in internetional clinical trials in oncology</article-title><source>J Nat Cancer inst</source><year>1993</year><volume>85</volume><fpage>364</fpage><lpage>376</lpage></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Guillemin</surname><given-names>F</given-names></name><name><surname>Bombardier</surname><given-names>C</given-names></name><name><surname>Beaton</surname><given-names>D</given-names></name><article-title>Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines</article-title><source>J Clin Epidemiol</source><year>1993</year><volume>46</volume><issue>12</issue><fpage>1417</fpage><lpage>1432</lpage><pub-id pub-id-type="doi">10.1016/0895-4356(93)90142-N</pub-id><pub-id pub-id-type="pmid">8263569</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Lohr</surname><given-names>KN</given-names></name><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Alomso</surname><given-names>J</given-names></name><name><surname>Burnam</surname><given-names>MA</given-names></name><name><surname>Patrick</surname><given-names>DL</given-names></name><name><surname>Perrin</surname><given-names>EB</given-names></name><name><surname>Roberts</surname><given-names>JS</given-names></name><article-title>Evaluating quality-of-life and health-status instrument: development of scientific review criteria</article-title><source>Clin Ther</source><year>1996</year><volume>18</volume><fpage>979</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1016/S0149-2918(96)80054-3</pub-id><pub-id pub-id-type="pmid">8930436</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Herdman</surname><given-names>M</given-names></name><name><surname>Fox-Rushby</surname><given-names>J</given-names></name><name><surname>Badia</surname><given-names>X</given-names></name><article-title>A model of equivalence in the cultural adptation of HRQL instruments: the universalist approach</article-title><source>Qual Life Res</source><year>1998</year><volume>7</volume><fpage>323</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1023/A:1008846618880</pub-id><pub-id pub-id-type="pmid">9610216</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Beaton</surname><given-names>D</given-names></name><name><surname>Bombardier</surname><given-names>C</given-names></name><name><surname>Guillemin</surname><given-names>F</given-names></name><name><surname>Ferraz</surname><given-names>MB</given-names></name><article-title>Guidelines for the process of cross-cultural adaptation of self-report measures</article-title><source>SPINE</source><year>2000</year><volume>25</volume><issue>24</issue><fpage>3186</fpage><lpage>3191</lpage><pub-id pub-id-type="doi">10.1097/00007632-200012150-00014</pub-id><pub-id pub-id-type="pmid">11124735</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="book"><name><surname>Streiner</surname><given-names>DL</given-names></name><name><surname>Norman</surname><given-names>GR</given-names></name><source>Health Measurment Scales. Apractical Guide to Their Development and use</source><year>2003</year><edition>Third</edition><publisher-name>Oxford: Oxford University Press</publisher-name></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="book"><collab>Khoudri</collab><source>36th Congress of the SRLF</source><year>2008</year><publisher-name>Paris: </publisher-name></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="book"><name><surname>Fayers</surname><given-names>PM</given-names></name><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Bjordal</surname><given-names>K</given-names></name><name><surname>Groenvold</surname><given-names>M</given-names></name><name><surname>Curran</surname><given-names>D</given-names></name><name><surname>Bottomley</surname><given-names>A</given-names></name><etal></etal><source>The EORTC QLQ-C30 Scoring Manual</source><year>2001</year><edition>3</edition><publisher-name>Brussels: European Organisation for Research and Treatment of Cancer</publisher-name></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Cronbach</surname><given-names>LJ</given-names></name><article-title>Coefficient alpha and the internal structure of tests</article-title><source>Psychometrika</source><year>1951</year><volume>16</volume><fpage>297</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1007/BF02310555</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Bullinger</surname><given-names>M</given-names></name><name><surname>Ahmedzai</surname><given-names>S</given-names></name><article-title>A modular approach to quality-of-life assessment in cancer clinical trials</article-title><source>Recent Results Cancer Res</source><year>1988</year><volume>111</volume><fpage>231</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1007/978-3-642-83419-6_27</pub-id><pub-id pub-id-type="pmid">2459750</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Ahmedzai</surname><given-names>S</given-names></name><name><surname>Bergman</surname><given-names>B</given-names></name><name><surname>Bullinger</surname><given-names>M</given-names></name><name><surname>Cull</surname><given-names>A</given-names></name><name><surname>Duez</surname><given-names>NJ</given-names></name><name><surname>Filiberti</surname><given-names>A</given-names></name><name><surname>Flechtner</surname><given-names>H</given-names></name><name><surname>Fleishman</surname><given-names>SB</given-names></name><name><surname>de Haes</surname><given-names>JCJM</given-names></name><name><surname>Kaasa</surname><given-names>S</given-names></name><name><surname>Klee</surname><given-names>M</given-names></name><name><surname>Osoba</surname><given-names>D</given-names></name><name><surname>Razavi</surname><given-names>D</given-names></name><name><surname>Rofe</surname><given-names>PB</given-names></name><name><surname>Schraub</surname><given-names>S</given-names></name><name><surname>Sneeuw</surname><given-names>K</given-names></name><name><surname>Sullivan</surname><given-names>M</given-names></name><name><surname>Takeda</surname><given-names>F</given-names></name><article-title>The European Organization of Research and Treatment of cancer QLQ-C30: a quality-of-life instrument for use in internationl clinical trials in oncology</article-title><source>J Nat Cancer Inst</source><year>1993</year><volume>85</volume><issue>5</issue><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1093/jnci/85.5.365</pub-id><pub-id pub-id-type="pmid">8433390</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Montazeri</surname><given-names>A</given-names></name><name><surname>Harirchi</surname><given-names>I</given-names></name><name><surname>Vahdani</surname><given-names>M</given-names></name><name><surname>Khaleghi</surname><given-names>F</given-names></name><name><surname>Jarvandi</surname><given-names>S</given-names></name><name><surname>Ebrahimi</surname><given-names>M</given-names></name><article-title>The European Organization for Research and Treatment of Cancer Qualitu of Life Questionnaire (EORTC QLQ-C30): translation and validation study of the Iranian version</article-title><source>Support Care Cancer</source><year>1999</year><volume>7</volume><issue>6</issue><fpage>400</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1007/s005200050300</pub-id><pub-id pub-id-type="pmid">10541982</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Yun</surname><given-names>YH</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>ES</given-names></name><name><surname>Bang</surname><given-names>SM</given-names></name><name><surname>Heo</surname><given-names>DS</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>You</surname><given-names>CH</given-names></name><name><surname>West</surname><given-names>K</given-names></name><article-title>Validation of the Korean version of the EORTC QLQ-C30</article-title><source>Qual Life Res</source><year>2004</year><volume>13</volume><issue>4</issue><fpage>863</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">15129896</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Kanda</surname><given-names>K</given-names></name><article-title>Translation and validation of the standard Chinese version of the EORTC QLQ-C30</article-title><source>Qual Life Res</source><year>2000</year><volume>9</volume><issue>2</issue><fpage>129</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1023/A:1008981520920</pub-id><pub-id pub-id-type="pmid">10983477</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Hoopman</surname><given-names>R</given-names></name><name><surname>Muller</surname><given-names>MJ</given-names></name><name><surname>Terwee</surname><given-names>CB</given-names></name><name><surname>Aaronson</surname><given-names>NK</given-names></name><article-title>Translation and validation of the EORTC QLQ-C30 for use among Turkish and Moroccan ethnic minority cancer patients in the Netherlands</article-title><source>Eur J Cancer</source><year>2006</year><volume>42</volume><fpage>1839</fpage><lpage>1847</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2005.08.047</pub-id><pub-id pub-id-type="pmid">16750911</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Feeny</surname><given-names>DH</given-names></name><name><surname>Patrick</surname><given-names>DL</given-names></name><article-title>Measurment health-related quality of life</article-title><source>Ann Intern Med</source><year>1993</year><volume>118</volume><fpage>622</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-118-8-199304150-00009</pub-id><pub-id pub-id-type="pmid">8452328</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Linguistique/explor/TamazightV2/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000147 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000147 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Linguistique
|area= TamazightV2
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |